Sökning: "Andrew C Hooker"

Hittade 5 avhandlingar innehållade orden Andrew C Hooker.

  1. 1. Methodology for Handling Missing Data in Nonlinear Mixed Effects Modelling

    Författare :Åsa M. Johansson; Mats O. Karlsson; Andrew C. Hooker; Leon Aarons; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacometrics; population models; censored observations; missing covariates; missing dependent variable; missing data mechanism; missing completely at random MCAR ; missing at random MAR ; missing not at random MNAR ; estimation algorithms; Pharmaceutical Science; Farmaceutisk vetenskap;

    Sammanfattning : To obtain a better understanding of the pharmacokinetic and/or pharmacodynamic characteristics of an investigated treatment, clinical data is often analysed with nonlinear mixed effects modelling. The developed models can be used to design future clinical trials or to guide individualised drug treatment. LÄS MER

  3. 2. Nonlinear Mixed Effects Methods for Improved Estimation of Receptor Occupancy in PET Studies

    Författare :Matts Kågedal; Mats Karlsson; Andrew C Hooker; Gitte Knudsen; Uppsala universitet; []
    Nyckelord :NATURVETENSKAP; NATURAL SCIENCES; PET; positron emission tomography; receptor occupancy; nonlinear mixed effects; NONMEM; optimal design; dose finding; Pharmacokinetics and Drug Therapy; Farmakokinetik och läkemedelsterapi;

    Sammanfattning : Receptor occupancy assessed by Positron Emission Tomography (PET) can provide important translational information to help bridge information from one drug to another or from animal to man. The aim of this thesis was to develop nonlinear mixed effects methods for estimation of the relationship between drug exposure and receptor occupancy for the two mGluR5 antagonists AZD9272 and AZD2066 and for the 5HT1B receptor antagonist AZD3783. LÄS MER

  4. 3. Practical Optimal Experimental Design in Drug Development and Drug Treatment using Nonlinear Mixed Effects Models

    Författare :Joakim Nyberg; Andrew C. Hooker; Mats O. Karlsson; Sergei Leonov; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacometrics; optimal design; nonlinear mixed effects models; robust design; optimizing drug development; population models; Pharmacokinetics and Drug Therapy; Farmakokinetik och läkemedelsterapi;

    Sammanfattning : The cost of releasing a new drug on the market has increased rapidly in the last decade. The reasons for this increase vary with the drug, but the need to make correct decisions earlier in the drug development process and to maximize the information gained throughout the process is evident. LÄS MER

  5. 4. Novel Pharmacometric Methods for Design and Analysis of Disease Progression Studies

    Författare :Sebastian Ueckert; Andrew C. Hooker; Mats O. Karlsson; Kayode Ogungbenro; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; pharmacometrics; optimal design; non-linear mixed effects models; degenerative diseases; Alzheimer s disease; item response theory; statistical power; Pharmaceutical Science; Farmaceutisk vetenskap;

    Sammanfattning : With societies aging all around the world, the global burden of degenerative diseases is expected to increase exponentially. From the perspective drug development, degenerative diseases represent an especially challenging class. LÄS MER

  7. 5. Model-Based Optimization of Clinical Trial Designs

    Författare :Camille Vong; Mats O. Karlsson; Andrew C. Hooker; Lena E. Friberg; Marylore Chenel; Oliver Sander; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; nonlinear mixed-effects models; pharmacometrics; likelihood ratio test; NONMEM; power; sample size; study design; proof-of-concept; dose-finding; population optimal design; LOQ; BQL data; neutropenia; docetaxel; myelosuppression; thrombocytopenia; MTD; Bayesian methods; 3 3 algorithm; dose escalation study; Pharmaceutical Science; Farmaceutisk vetenskap;

    Sammanfattning : General attrition rates in drug development pipeline have been recognized as a necessity to shift gears towards new methodologies that allow earlier and correct decisions, and the optimal use of all information accrued throughout the process. The quantitative science of pharmacometrics using pharmacokinetic-pharmacodynamic models was identified as one of the strategies core to this renaissance. LÄS MER